IPP Bureau
Dr. Reddy's Laboratories asked to pay $462.5 mn to Hatchtech
By IPP Bureau - June 17, 2021
The company is exploring all legal options to challenge the award.
Zydus Cadila receives tentative USFDA approval for Brivaracetam
By IPP Bureau - June 15, 2021
The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad
Govt. to increase Janaushadhi Kendras to 10,000
By IPP Bureau - June 15, 2021
Under the PMBJP, all the districts of the country are covered and ensure easy reach of affordable medicine to the people in every nook and corner of the country
Jubilant HollisterStier to manufacture COVID-19 Vaccine COVAXIN in US
By IPP Bureau - June 15, 2021
Entered into a manufacturing partnership with Ocugen, Inc. for manufacturing of COVID-19 vaccine COVAXIN for the US and Canadian markets
JB Chemicals PAT jumps by 101% to Rs101 Cr
By IPP Bureau - June 15, 2021
The company recorded revenue of Rs 528crore as compared to Rs 444 crore, registering a growth of 19% over the corresponding quarter ended 31st March 2020
Sun Pharma’s US Specialty business to grow at 21% CAGR in 2 years
By IPP Bureau - June 14, 2021
The company expects to see steady performance led by new launches and gradual normalization post the scale-up in vaccination
Lupin receives warning letter from U.S. FDA
By IPP Bureau - June 14, 2021
The company does not believe that the warning letter will have an impact on disruption of supplies or the existing revenues from operations of this facility
Lupin donates Oxygen generation plants in Mah, MP & Gujarat
By IPP Bureau - June 12, 2021
These five oxygen plants with a total capacity of 3,840 cubic meters of oxygen per day have been donated to Madhya Pradesh, Maharashtra, and Gujarat
IPCA Laboratories increases stake in Trophic Wellness to 52.35%
By IPP Bureau - June 12, 2021
With the acquisition of these further shares, TWPL has now become company's subsidiary.
Alkem launches Perampil tablets at affordable prices
By IPP Bureau - June 11, 2021
The company has launched Perampil, at 2 mg (Rs. 49/strip of 7 tablets), 4 mg (Rs. 180/strip of 15 tablets) and 6 mg (Rs. 300/strip of 15 tablets) to improve patient access
CSIR join hands with SUVEN Pharmaceuticals
By IPP Bureau - June 11, 2021
The agreements between the parties involve a total fee of Rs. 8 lakh plus taxes for the grant of the licenses on a non-exclusive basis to SPL
Glenmark's interim data from PMS Study on Favipiravir released
By IPP Bureau - June 09, 2021
The study was conducted in patients with mild to moderate COVID-19
Lupin launches Digital Asthma Educator platform
By IPP Bureau - June 08, 2021
The new platform is the latest initiative under Lupin’s long running umbrella programme, Joint Airways Initiative (JAI), for patients suffering from respiratory ailment
Trials of three more vaccines are in advanced stage: Modi
By IPP Bureau - June 08, 2021
The Prime Minister announced that 21st June onwards, the Government of India will provide free vaccines to all Indian citizens above 18 years of age
Glenmark receives ANDA approval for theophylline extended-release tablets
By IPP Bureau - June 07, 2021
Glenmark has been granted a competitive generic therapy (CGT) designation for theophylline extended-release tablets
